-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target

Benzinga·06/24/2026 10:50:24
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $20 price target.